The Second Clinical Medical College of Shanxi Medical University, Taiyuan 030000, China.
Department of Endocrinology, Second Hospital of Shanxi Medical University, Taiyuan 030000, China.
J Clin Endocrinol Metab. 2023 Sep 18;108(10):2728-2738. doi: 10.1210/clinem/dgad172.
According to growing research, C1q/TNF-Related Protein-9 (CTRP9) appears to be linked to type 2 diabetes mellitus (T2DM). But the literature on circulating levels of CTRP9 in patients with T2DM has been contradictory.
This is a systematic review and meta-analysis to reassess the circulating level of CTRP9 in patients with T2DM, with and without complications.
Relevant studies published until October 31, 2021, were identified from the PubMed, Embase, Web of Science, Cochrane Library, WanFang, CNKI, VIP, and CBM databases. Participants with age ≥18 years with clinically diagnosed T2DM were included. Sex and diabetes complications were not restricted. The data were extracted by 2 reviewers independently using a standard data collection form.
Analysis demonstrated significantly lower circulating levels of CTRP9 in patients with T2DM than in patients without diabetes (standardized mean difference [SMD] = -1.36; 95% CI -1.78 to -0.93; P < .001), I2 = 97.5%, P < .001). Furthermore, the circulating level of CTRP9 in patients with T2DM-related complications was lower than that in patients with T2DM without complications, regardless of macrovascular complications or microvascular complications (SMD = -1.062; 95% CI -1.466 to -0.658; P < .001, I2 = 91.3%, P < .001). Subgroup analyses revealed that factors such as body mass index, T2DM duration, and fasting blood glucose were the sources of heterogeneity (P = .047, P = .034, and P = .07, respectively).
The present systematic review and meta-analysis found CTRP9 levels were lower in T2DM patients with or without complications. However, since this was a meta-analysis of most observational studies, these findings still need to be verified by further studies with a large sample size.
越来越多的研究表明,C1q/TNF 相关蛋白-9(CTRP9)似乎与 2 型糖尿病(T2DM)有关。但是,关于 T2DM 患者循环 CTRP9 水平的文献一直存在争议。
这是一项系统评价和荟萃分析,旨在重新评估 T2DM 患者伴或不伴并发症时循环 CTRP9 水平。
从 PubMed、Embase、Web of Science、Cochrane 图书馆、万方、中国知网、维普及中国生物医学文献数据库检索截至 2021 年 10 月 31 日发表的相关研究。纳入年龄≥18 岁、临床诊断为 T2DM 的患者。不限制性别和糖尿病并发症。由 2 位研究者独立使用标准数据采集表提取数据。
分析显示,与无糖尿病患者相比,T2DM 患者的循环 CTRP9 水平显著降低(标准化均数差[SMD]=-1.36;95%CI-1.78 至-0.93;P<.001),I²=97.5%,P<.001)。此外,无论是否存在大血管并发症或微血管并发症,T2DM 相关并发症患者的循环 CTRP9 水平均低于 T2DM 无并发症患者(SMD=-1.062;95%CI-1.466 至-0.658;P<.001,I²=91.3%,P<.001)。亚组分析显示,体重指数、T2DM 病程和空腹血糖等因素是异质性的来源(P=.047、P=.034 和 P=.07)。
本系统评价和荟萃分析发现,T2DM 患者伴或不伴并发症时,CTRP9 水平均较低。然而,由于这是一项针对大多数观察性研究的荟萃分析,这些发现仍需要进一步的大样本量研究来验证。